Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs
Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.
EP: 1.Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs
EP: 2.Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs
EP: 3.Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs
EP: 4.Best Practices for Managing EGFR Tyrosine Kinase Inhibitor–Related Adverse Events
EP: 5.Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs
EP: 6.Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs
EP: 7.Experts Discuss Common AEs With EGFR TKIs
EP: 8.Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC
EP: 9.Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs
EP: 10.Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs
EP: 11.Experts on the Management of Diarrhea Associated With EGFR TKIs
Emily Skotte, MSN, assistant in medicine, Nursing School, Division of Hematology Oncology, Vanderbilt University Medical Center, discusses common ways to manage the rashes that may occur as adverse effects (AEs) in patients treated with EGFR TKIs.
Telling patients up front that they may experience rash as an AE of their TKI treatment allows them to proactively begin to use topical steroid creams, Skotte says. Immediate use of a cream can help lessen the severity of the rash or stop the progression at grade 3, Skotte explains. While topical creams are usually recommended, patients should communicate their use of these creams with their treating physicians, Skotte notes.
If the rash occurs on the face, an antibiotic gel or ointment like clindamycin may be effective, especially as facial rashes can be more distressing, Skotte says. The standards of care for these rashes are shifting more toward antibiotic topical creams, rather than pills, Skotte notes. Because the TKIs patients are taking will hopefully have long-term efficacy, AEs may occur for the duration of their treatment. As such, one main goal of rash management is to spare patients exposure to oral antibiotics, Skotte concludes.
Sponsored by Takeda Oncology
